Structured laughter therapy improves breathing for COPD patients, study finds

Structured laughter therapy may help patients with Chronic Obstructive Pulmonary Disease (COPD) breathe more easily and improve their overall health. Findings from a randomized controlled trial presented at the European Respiratory Society (ERS) Congress in Barcelona indicate that the intervention performed similarly to standard breathing exercises.

Conducted at Ankara Bilkent City Hospital in Turkey, the study tracked 63 participants divided into three groups of 21: one receiving laughter therapy, one practicing pursed-lip breathing, and a control group. The laughter therapy group participated in 30-minute sessions three times per week for eight weeks. Researchers found that both the laughter therapy and pursed-lip breathing groups showed measurable improvements in breathing and health compared to the control group. These benefits persisted for at least one month after the trial concluded, though the therapy did not reduce the participants' dependence on caregivers.

The Mechanics of Laughter Therapy

COPD is a progressive disease characterized by air becoming trapped in the lungs during exhalation, which leads to chronic breathlessness. While standard treatments typically involve corticosteroids, bronchodilators, and pursed-lip breathing, researchers looked to laughter therapy due to its previous promise in treating cancer, kidney failure, and diabetes.

Unlike spontaneous laughter, this intervention follows a structured protocol. It includes relaxation techniques, rhythmic clapping, and playful exercises, such as mimicking the sounds of a lion or a motorcycle. According to Dr. Goncagul Aldan, this structured approach may help facilitate gentle air expulsion and reduce air trapping without overwhelming the respiratory system.

Industry Implications

If these results are validated in larger trials, laughter therapy could provide a significant shift in how COPD is managed. Because the therapy requires no specialized equipment or expensive medication, it offers a highly accessible self-management tool for patients globally. Marc Miravitlles noted that the simplicity and low cost of the therapy mean it could potentially be used by anyone, anywhere in the world.

For a patient population that often struggles with the physical and financial burdens of chronic care, a non-invasive, low-cost supplement to medical treatment could substantially improve daily quality of life.

Future Outlook

While the initial results are promising, the small sample size of 63 participants means the findings are preliminary. Future research will need to determine if these benefits scale across larger, more diverse populations and whether the improvements in breathing translate to long-term clinical outcomes. For now, the study establishes a foundation for laughter therapy as a viable complementary tool in respiratory rehabilitation.